{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:27:54Z","timestamp":1766050074546,"version":"3.37.3"},"reference-count":15,"publisher":"Endocrinology Research Centre","issue":"3","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p><jats:bold>AIM.<\/jats:bold> To present a clinical case of reversible hypopituitarism due to hypophysitis developed after COVID-19 infection.<\/jats:p><jats:p><jats:bold>MATERIALS AND METHODS<\/jats:bold>. A patient with residual clinical manifestations of hypopituitarism underwent clinical evaluation at the time of symptoms of hypopituitarism and in follow-up. Morning serum cortisol (171\u2013536 nmol\/l) was measured by electrochemiluminescence immunoassay. Morning ACTH (7.2\u201363.3 pg\/ml), prolactin (66\u2013436\u00a0mU\/l), TSH (0.25\u20133.5\u00a0mIU\/L), fT4 (9\u201319\u00a0pmol\/l) and fT3 (2.6\u20135.7\u00a0pmol\/l) were measured by chemiluminescence immunoassay. Data were analyzed throughout the course of the disease.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold>. A 35-year-old female developed\u00a0clinical symptoms of hypopituitarism two months after recovery from a confirmed COVID-19 infection. Laboratory investigation confirmed hypocorticism, hypothyroidism, hypogonadism and the patient was prescribed appropriate hormonal therapy in January 2021. Four months later the symptoms were alleviated (April 2021) and there were signs of recovery shown by imaging and hormonal: morning serum cortisol 227 nmol\/l, morning ACTH 33.96 pg\/ml, prolactin 68.3 mU\/l, TSH 2.626 mIU\/L, fT4 10.75 pmol\/l, fT3\u00a03.96 pmol\/l. Thyroid hormone was discontinued, but hypogonadism and hypocorticism persisted with estradiol \u2014 51.48 pmol\/l, 24h urine cortisol level \u2014 41.8 nmol\/day. MRI results showed that the signs of hypophysitis were alleviated in comparison with MRI from January 2021. Full recovery of pituitary axis was reported in October 2021, with recovery of normal menstrual cycle.\u00a0Furthermore, hormonal profile was likewise normal.<\/jats:p><jats:p><jats:bold>CONCLUSION<\/jats:bold>. This report provides evidence of delayed damage to the pituitary gland after infection with the COVID-19, with recovery of its function and structure. To date, the mechanisms of such an impact are not entirely clear; further collection of data on such cases and analysis is required.<\/jats:p>","DOI":"10.14341\/probl12896","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T06:38:39Z","timestamp":1657953519000},"page":"50-56","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":13,"title":["Hypophysitis and reversible hypopituitarism developed after COVID-19 infection \u2014 a clinical case report"],"prefix":"10.14341","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4503-7248","authenticated-orcid":true,"given":"N. Yu.","family":"Gorbova","sequence":"first","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7775-7568","authenticated-orcid":true,"given":"V P.","family":"Vladimirova","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7041-0732","authenticated-orcid":true,"given":"L. Y.","family":"Rozhinskaya","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6674-6441","authenticated-orcid":true,"given":"Zh. Y.","family":"Belaya","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5458","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Munblit D, Nekliudov NA, Bugaeva P, et al. Stop COVID Cohort: An Observational Study of 3480 Patients Admitted to the Sechenov University Hospital Network in Moscow City for Suspected Coronavirus Disease 2019 (COVID-19) Infection. Clin Infect Dis. 2021;73(1):1-11. doi: https:\/\/doi.org\/10.1093\/cid\/ciaa1535","DOI":"10.1093\/cid\/ciaa1535"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Puig-Domingo M, Marazuela M, Giustina A. COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Endocrine. 2020;68(1):2-5. doi: https:\/\/doi.org\/10.1007\/s12020-020-02294-5","DOI":"10.1007\/s12020-020-02294-5"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Lisco G, De Tullio A, Stragapede A, et al. Covid-19 and the endocrine system: A comprehensive review on the theme. J Clin Med. 2021;10(13):2920. doi: https:\/\/doi.org\/10.3390\/jcm10132920","DOI":"10.3390\/jcm10132920"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Belaya Z, Golounina O, Melnichenko G, et al. Clinical course and outcome of patients with ACTH-dependent Cushing\u2019s syndrome infected with novel coronavirus disease-19 (COVID-19): case presentations. Endocrine. 2021;72(1):12-19. doi: https:\/\/doi.org\/10.1007\/s12020-021-02674-5","DOI":"10.1007\/s12020-021-02674-5"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Salamanna F, Maglio M, Borsari V, et al. Blood factors as biomarkers in osteoporosis: points from the COVID-19 era. Trends Endocrinol Metab. 2021;32(9):672-679. doi: https:\/\/doi.org\/10.1016\/j.tem.2021.05.005","DOI":"10.1016\/j.tem.2021.05.005"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Hampson G, Stone M, Lindsay JR, et al. Diagnosis and Management of Osteoporosis During COVID-19: Systematic Review and Practical Guidance. Calcif Tissue Int. 2021;109(4):351-362. doi: https:\/\/doi.org\/10.1007\/s00223-021-00858-9","DOI":"10.1007\/s00223-021-00858-9"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Atmaca A, Demirci I, Haymana C, et al. No association of antiosteoporosis drugs with COVID-19-related outcomes in women: a nationwide cohort study. Osteoporos Int. 2022;33(1):273-282. doi: https:\/\/doi.org\/10.1007\/s00198-021-06067-2","DOI":"10.1007\/s00198-021-06067-2"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Gubbi S, Hannah-Shmouni F, Verbalis JG, Koch CA. Hypophysitis: An update on the novel forms, diagnosis and management of disorders of pituitary inflammation. Best Pract Res Clin Endocrinol Metab. 2019;33(6):101371. doi: https:\/\/doi.org\/10.1016\/j.beem.2019.101371","DOI":"10.1016\/j.beem.2019.101371"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Joshi MN, Whitelaw BC, Carroll PV. Mechanisms in endocrinology: Hypophysitis: diagnosis and treatment. Eur J Endocrinol. 2018;179(3):R151-R163. doi: https:\/\/doi.org\/10.1530\/EJE-17-0009","DOI":"10.1530\/EJE-17-0009"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Pena JA, Birchansky S, Lotze TE. Lymphocytic Hypophysitis Associated With Pediatric Multiple Sclerosis. Pediatr Neurol. 2014;51(4):580-582. doi: https:\/\/doi.org\/10.1016\/j.pediatrneurol.2014.06.005","DOI":"10.1016\/j.pediatrneurol.2014.06.005"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Lundholm MD, Poku C, Emanuele N, et al. SARS-CoV-2 (COVID-19) and the Endocrine System. J Endocr Soc. 2020;4(11):580-582. doi: https:\/\/doi.org\/10.1210\/jendso\/bvaa144","DOI":"10.1210\/jendso\/bvaa144"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Pal R, Banerjee M. COVID-19 and the endocrine system: exploring the unexplored. J Endocrinol Invest. 2020;43(7):1027-1031. doi: https:\/\/doi.org\/10.1007\/s40618-020-01276-8","DOI":"10.1007\/s40618-020-01276-8"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Frara S, Allora A, Castellino L, et al. COVID-19 and the pituitary. Pituitary. 2021;24(3):465-481. doi: https:\/\/doi.org\/10.1007\/s11102-021-01148-1","DOI":"10.1007\/s11102-021-01148-1"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Kaya MG. Pituitary Insufficiency Diagnosed After Coronavirus Disease-19: A Case Report. Erciyes Med J. 2021;24(3):465-481. doi: https:\/\/doi.org\/10.14744\/etd.2021.30676","DOI":"10.14744\/etd.2021.30676"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Shekhar S, Wurth R, Kamilaris CDC, et al. Endocrine Conditions and COVID-19. Horm Metab Res. 2020;52(07):471-484. doi: https:\/\/doi.org\/10.1055\/a-1172-1352","DOI":"10.1055\/a-1172-1352"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/12896\/10274","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T06:39:19Z","timestamp":1657953559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/12896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,7,15]]}},"URL":"https:\/\/doi.org\/10.14341\/probl12896","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"type":"electronic","value":"2308-1430"},{"type":"print","value":"0375-9660"}],"subject":[],"published":{"date-parts":[[2022,3,24]]}}}